Lomustine in Addition to Standard of Care in Patients With MGMT Methylated Glioblastoma

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

December 1, 2024

Primary Completion Date

December 15, 2028

Study Completion Date

December 15, 2031

Conditions
Glioblastoma, IDH-wildtypeMGMT-Methylated Glioblastoma
Interventions
DRUG

Temozolomide

In the experimental treatment arm: a combination of Temozolomide and Lomustine, taken together, two separate pills

DRUG

Lomustine

In the experimental treatment arm: a combination of Temozolomide and Lomustine, taken together, two separate pills

All Listed Sponsors
collaborator

Skane University Hospital

OTHER

collaborator

Gävle Hospital

OTHER

collaborator

Karolinska Institutet

OTHER

collaborator

Sahlgrenska University Hospital

OTHER

collaborator

Karlstad Central Hospital

OTHER

collaborator

Ryhov County Hospital

OTHER

collaborator

Kalmar County Hospital

OTHER

collaborator

Oslo University Hospital

OTHER

collaborator

St. Olavs Hospital

OTHER

collaborator

Haukeland University Hospital

OTHER

collaborator

Sorlandet Hospital HF

OTHER_GOV

collaborator

Helse Stavanger HF

OTHER_GOV

collaborator

Aarhus University Hospital

OTHER

collaborator

University Hospital, Umeå

OTHER

collaborator

Eskilstuna Lasarettet

OTHER

collaborator

Region Örebro County

OTHER

lead

Vastra Gotaland Region

OTHER_GOV

NCT06419946 - Lomustine in Addition to Standard of Care in Patients With MGMT Methylated Glioblastoma | Biotech Hunter | Biotech Hunter